Studying how body weight affects prostate cancer tissue and its immune cells
Examines prostate tumor tissue from patients with a higher or lower body mass index.
Plain-language title generated from the registry record
Registry title: Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression
Key facts
- Where
- Milan, ItalySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with prostate cancer. Researchers study prostate cancer tissue from people with and without a high body weight.
- Age
- 18 years and older
- Sex
- Men only
Read by machine on 12 November 2026.
Where in Italy
- IRCCS Cà Granda Ospedale Maggiore Policlinico MilanoMilan, ItalyContact: giancarlo albo, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- Trial code
- NCT06292897
- Record updated
- 5 March 2024
- Original description
Evaluate the protein expression of lactate dehydrogenase enzyme (LDHA) and MCT-1/-4 transporters, involved in lactate synthesis and transport, in prostate carcinoma tissues from severely overweight/obese (BMI > 27.5) and non-severely overweight/normoweight (BMI < 27.5) patients affected by prostate carcinoma.Read full original descriptionShow less
Integrating Tissue-based Spatial Information to Elucidate How Obesity-induced Tumour Metabolites Drive Prostate Cancer Progression
Evaluate the protein expression of lactate dehydrogenase enzyme (LDHA) and MCT-1/-4 transporters, involved in lactate synthesis and transport, in prostate carcinoma tissues from severely overweight/obese (BMI > 27.5) and non-severely overweight/normoweight (BMI < 27.5) patients affected by prostate carcinoma.
ii. Characterize the immune infiltrate in the prostate carcinoma of the aforementioned patients.
iii. Assess the association between intra-tumoral lactate accumulation (using LDHA and MCT-4 protein expression levels as readouts) and alterations in the tumor immune microenvironment and/or deregulation of relevant oncogenic pathways.
Inclusion: affected by prostate cancer.
Exclusion: -.